Technology

ExacTcell: Highly Purified, Target-Specific Cytotoxic CD8+ T Lymphocyte (CTL)

Killer T cells are white blood cells that play a vital role in the immune system’s defense against diseases, including viruses and cancer. Most cytotoxic T lymphocytes (CTLs), including those developed with the ExacTcell technology, express T cell receptors (TCRs). These surface proteins endow each T cell with a unique immune specificity, enabling them to recognize and respond to specific foreign antigenic peptides presented on infected or malignant cells in combination with an HLA molecule.

Our patented ExacTcell technology harness the cytotoxic or killer T cell. We believe that ExacTcell has the potential to be a broadly applicable approach for developing convenient and reasonably priced cellular immunotherapies for the treatment of acute viral infections, long-term consequences of viral infections, viral and non-viral induced cancers.

Human Leukocyte Antigens (HLA) show foreign protein to T cells. HLA varies from person to person. For this reason, a panel of T cells is necessary to match a variety of HLA types.

Mechanism of Action

Our patented approach, using pre-defined T cell targets, allows virus infected cells, viral induced cancer cells, and several non-virally induced cancers to be directly targeted by ExacTcell products. Nature uses this approach to rid us of virus infections. Many cancer cells can be targeted and killed in the same way. 

Development

Tevogen’s commercial scale ready manufacturing process yields a highly efficient ratio of doses per cell donor.

ExacTcell focuses on the selection and expansion of naturally occurring, genetically unmodified T cells to target multiple, distinct, preselected proteins present only on virus-infected or malignant cells and to kill those cells.

We believe that by relying on CD8+ CTLs, ExacTcell has the potential to produce an entirely new class of drugs that could present numerous benefits over competitive platforms. In contrast to other approaches, our ExacTcell technology enables a single, specific HLA molecule to be targeted in a clinical product and the specific target peptides to be known with certainty and precision.

Tevogen’s commercial scale ready first generation manufacturing process already yields a highly efficient ratio of doses per cell donor. The second generation, Tevogen’s proprietary TCR-T process, is expected to dramatically increase the number of doses.

Benefits and Uniqueness

---